Cosentyx PMR Data Positive, but LOE Overhang Remains

What happened

Novartis announced that its Phase III REPLENISH trial for Cosentyx in polymyalgia rheumatica (PMR) achieved statistically significant sustained remission and steroid-sparing effects versus placebo, with results published in the New England Journal of Medicine and presented at EULAR. While the data demonstrates Cosentyx's potential in a new autoimmune indication, the drug already faces generic erosion and slowing growth in its established markets, as highlighted in the DeepValue master report. The report rates Novartis a Potential Sell, citing Entresto and Cosentyx LOE headwinds that require strong offset from Kisqali, Kesimpta, Pluvicto, and Scemblix. The PMR indication is still investigational and years away from material revenue, so near-term financial impact is minimal. This data modestly improves Cosentyx's long-term outlook but does not alter the core thesis that Novartis must successfully navigate multiple patent cliffs to sustain its 5-6% growth target.

Implication

If approved, Cosentyx PMR could add $1-2 billion in peak sales, partially offsetting the $3-4 billion LOE drag from Entresto and Cosentyx existing indications. However, the investment thesis remains dependent on sustained growth from Kisqali, Kesimpta, Pluvicto, and Scemblix, as well as successful integration of Avidity and other pipeline assets. Investors should view this as a positive option value but not a thesis-changer until regulatory and commercial milestones are achieved.

Thesis delta

The REPLENISH data introduces upside optionality for Cosentyx, potentially extending its lifecycle and reducing the LOE drag on Novartis’s growth narrative. However, the core thesis remains intact: Novartis’s premium valuation already prices in strong offset from other growth brands, and the PMR data does not address the near-term Entresto erosion or margin dilution from large acquisitions. The market’s reaction may be positive, but the fundamental risk-reward skews negative unless the broader growth portfolio delivers.